Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

A single institution's experience with surgical cytoreduction of stage IV, well-differentiated, small bowel neuroendocrine tumors.

Boudreaux JP, Wang YZ, Diebold AE, Frey DJ, Anthony L, Uhlhorn AP, Ryan P, Woltering EA.

J Am Coll Surg. 2014 Apr;218(4):837-44. doi: 10.1016/j.jamcollsurg.2013.12.035. Epub 2014 Jan 10.

PMID:
24655881
2.

Outcome of surgery for ileojejunal neuroendocrine tumors.

Habbe N, Fendrich V, Heverhagen A, Ramaswamy A, Bartsch DK.

Surg Today. 2013 Oct;43(10):1168-74. doi: 10.1007/s00595-012-0408-1. Epub 2012 Nov 11.

PMID:
23143168
3.

The palliative benefit of aggressive surgical intervention for both hepatic and mesenteric metastases from neuroendocrine tumors.

Chambers AJ, Pasieka JL, Dixon E, Rorstad O.

Surgery. 2008 Oct;144(4):645-51; discussion 651-3. doi: 10.1016/j.surg.2008.06.008.

PMID:
18847650
4.

Resection of at-risk mesenteric lymph nodes is associated with improved survival in patients with small bowel neuroendocrine tumors.

Landry CS, Lin HY, Phan A, Charnsangavej C, Abdalla EK, Aloia T, Nicolas Vauthey J, Katz MH, Yao JC, Fleming JB.

World J Surg. 2013 Jul;37(7):1695-700. doi: 10.1007/s00268-013-1918-8.

5.

Survival and prognostic factors in well-differentiated pancreatic neuroendocrine tumors.

Boyar Cetinkaya R, Vatn M, Aabakken L, Bergestuen DS, Thiis-Evensen E.

Scand J Gastroenterol. 2014 Jun;49(6):734-41. doi: 10.3109/00365521.2014.903432. Epub 2014 Mar 28.

PMID:
24679166
6.

Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors.

Norton JA, Kivlen M, Li M, Schneider D, Chuter T, Jensen RT.

Arch Surg. 2003 Aug;138(8):859-66.

PMID:
12912744
7.

[Extent of resection for neuroendocrine tumors of the small intestine].

Musholt TJ.

Chirurg. 2011 Jul;82(7):591-7. doi: 10.1007/s00104-011-2070-3. Review. German.

PMID:
21678105
8.

Surgery and staging of pancreatic neuroendocrine tumors: a 14-year experience.

Ito H, Abramson M, Ito K, Swanson E, Cho N, Ruan DT, Swanson RS, Whang EE.

J Gastrointest Surg. 2010 May;14(5):891-8. doi: 10.1007/s11605-010-1173-3. Epub 2010 Mar 12.

PMID:
20224984
9.

Discussion.

[No authors listed]

J Am Coll Surg. 2014 Apr;218(4):844-5. doi: 10.1016/j.jamcollsurg.2014.01.031. No abstract available.

PMID:
24655882
10.

Surgery for metastatic neuroendocrine tumors with occult primaries.

Bartlett EK, Roses RE, Gupta M, Shah PK, Shah KK, Zaheer S, Wachtel H, Kelz RR, Karakousis GC, Fraker DL.

J Surg Res. 2013 Sep;184(1):221-7. doi: 10.1016/j.jss.2013.04.008. Epub 2013 Apr 25.

PMID:
23643298
11.

Perforation through small bowel malignant tumors.

Chao TC, Chao HH, Jan YY, Chen MF.

J Gastrointest Surg. 2005 Mar;9(3):430-5.

PMID:
15749607
12.

Risk factors for disease progression in advanced jejunoileal neuroendocrine tumors.

Panzuto F, Campana D, Fazio N, Brizzi MP, Boninsegna L, Nori F, Di Meglio G, Capurso G, Scarpa A, Dogliotti L, De Braud F, Tomassetti P, Delle Fave G, Falconi M.

Neuroendocrinology. 2012;96(1):32-40. doi: 10.1159/000334038. Epub 2011 Dec 28.

PMID:
22205326
13.

Indication for liver transplantation in young patients with small intestinal NETs is rare?

Norlén O, Daskalakis K, Öberg K, Åkerström G, Stålberg P, Hellman P.

World J Surg. 2014 Mar;38(3):742-7.

PMID:
24233660
14.

Relapse factors for ileal neuroendocrine tumours after curative surgery: a retrospective French multicentre study.

Le Roux C, Lombard-Bohas C, Delmas C, Dominguez-Tinajero S, Ruszniewski P, Samalin E, Raoul JL, Renard P, Baudin E, Robaskiewicz M, Mitry E, Cadiot G; Groupe d'étude des Tumeurs Endocrines (GTE).

Dig Liver Dis. 2011 Oct;43(10):828-33. doi: 10.1016/j.dld.2011.04.021. Epub 2011 Jun 8.

PMID:
21641888
15.

Reappraisal of lymphatic mapping for midgut neuroendocrine patients undergoing cytoreductive surgery.

Wang YZ, Carrasquillo JP, McCord E, Vidrine R, Lobo ML, Zamin SA, Boudreaux P, Woltering E.

Surgery. 2014 Dec;156(6):1498-502; discussion 1502-3. doi: 10.1016/j.surg.2014.05.028. Epub 2014 Nov 11.

PMID:
25456941
16.

Adenocarcinoma of the small bowel: presentation, prognostic factors, and outcome of 217 patients.

Dabaja BS, Suki D, Pro B, Bonnen M, Ajani J.

Cancer. 2004 Aug 1;101(3):518-26.

17.

Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer.

Bristow RE, Montz FJ, Lagasse LD, Leuchter RS, Karlan BY.

Gynecol Oncol. 1999 Mar;72(3):278-87.

PMID:
10053096
18.

Feasibility study of two-stage hepatectomy for bilobar liver metastases.

Bowers KA, O'Reilly D, Bond-Smith GE, Hutchins RR.

Am J Surg. 2012 Jun;203(6):691-7. doi: 10.1016/j.amjsurg.2011.07.014. Epub 2011 Dec 7.

PMID:
22154136
19.

Long-term survival after surgical management of neuroendocrine hepatic metastases.

Glazer ES, Tseng JF, Al-Refaie W, Solorzano CC, Liu P, Willborn KA, Abdalla EK, Vauthey JN, Curley SA.

HPB (Oxford). 2010 Aug;12(6):427-33. doi: 10.1111/j.1477-2574.2010.00198.x.

20.

Survival and prognostic factor analysis of 146 metastatic neuroendocrine tumors of the mid-gut.

Strosberg J, Gardner N, Kvols L.

Neuroendocrinology. 2009;89(4):471-6. doi: 10.1159/000197899. Epub 2009 Jan 28.

PMID:
19174605
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk